Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Completed 2Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia, Plasma Cell 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1Hemangioma, Cavernous, Central Nervous System 1Corneal Diseases 1Blood Protein Disorders 1

Interventions

Dexamethasone 2daratumumab 1belantamab mafodotin 1Cyclophosphamide 1Bortezomib 14-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Immunoglobulin Light-chain Amyloidosis × daratumumab × Clear all
NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Peking University People's Hospital

Phase 2 Not yet recruiting
39 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡